On the other hand, dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduces hyperglycaemia independently of insulin by selectively inhibiting the SGLT2 transporter, promoting urinary glucose excretion. Here, SLC5A2 is linked to Hyperglycemia.